NCT00527930已完成2 期
Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer (MBC) Previously Treated With or Resistant to an Anthracycline and Taxane
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 87
- 试验地点
- 2
- 主要终点
- Response Rate
研究概览
简要总结
Phase II trial of oxaliplatin in combination with S-1(SOX) in patients with recurrent or metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline and taxane
详细描述
The main purpose of this study is to find out the efficacy and safety profile of TS-1 with oxaliplatin in previously anthracycline and taxane pretreated patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •M/F age ≥ 18
- •Metastatic(TxNxM1) or inoperable locally recurrent breast cancer(rT4NxM0) after taxane & anthracycline therapy
- •Measurable disease (RECIST) : A patient with at least one measurable lesion of which the diameter is confirmed to be 10mm in spiral CT or multidetector CT (MD CT), or 20 mm or longer in conventional CT
- •No prior treatment with S-1, capecitabine, platinum In metastatic setting
- •Must have received an anthracycline and taxane in adj. or metastatic settings (concurrent, sequential, or combined with other drugs)
- •For taxanes (Paclitaxel (P) / Docetaxel (D))
- •Must have progressed while or after receiving P or D (Patients who relapse within 12 months of completing adjuvant chemotherapy containing an anthracycline and a taxane, do not require prior chemotherapy for metastatic disease)
- •Only 1 adjuvant regimen permitted (neoadjuvant immediately followed by surgery and immediately followed by adj. is permitted)
- •For anthracyclines
- •Progressed while on anthracycline treatment, with or without initial response or
- •Have received an adequate course of anthracyclines defined as follows:
- •Adj.: Must have received a standard regimen (doxorubicin ≥ 240 mg/m2 or ≥ 360 mg/m2 epirubicin or equivalent)
- •Metastatic: Must have received a standard regimen(doxorubicin ≥300mg/m2 or equivalent)
- •Not candidate for Herceptin
- •ECOG PS ≤ 2
- •Completion of all prior chemotherapy ≥ 3 wks prior to enrol
- •Completion of hormonal therapy 2 wks prior to enroll
- •Resolution of all clinically significant toxic effects (excluding alopecia and sensory neuropathies) of any prior surgery or therapy to grade ≤ 1 (NCI CTCAE 3.0), for peripheral neuropathy grade ≤ 2 (NCI CTCAE 3.0), or to within the limits listed in the specific inclusion/exclusion criteria
- •A patient with the willingness to comply with the study protocol during the study period and capable of complying with it.
- •Informed consent obtained.
排除标准
- •WOCBP(woman of child bearing potential) unwilling to use acceptable method to avoid pregnancy
- •Breast feeding or pregnant women
- •Patients with Hx of symptomatic brain or leptomeningeal involvement (eligible if asymptomatic 2weeks after proper radiation therapy)
- •≥grade 3 neuropathy currently
- •Hx of second malignancy except adequately treated basal or squamous skin ca or CIS of cervix. Adequately treated contralateral breast ca with DF >5 yrs prior to this study is permitted
- •MI, unstable angina, CABG, clinically significant arrhythmia within 6 mo
- •Hx of inflammatory bowel disease or chronic diarrhea,
- •ANC < 1500, Plt < 100K, Hb <9.0
- •Ccr < 60 ml/min or creatinine >1.5
- •Bil > 1.5 x UNL, AST/ALT ≥ 2.5xUNL if hepatic meta + > 5xUNL)
- •History of hypersensitivity to 5-FU, platinum, or to compounds with similar chemical structures
- •More than 3 prior chemotherapy for metastatic or recurrent disease or prior treatment with S-1, capecitabine or any platinum analogs in metastatic setting (5-FU combine with other agent in metastatic setting is allowed_ ex) CMF, FAC)
- •Her2(+) pts who are candidates for Herceptin
- •prior surgery within 4 week
- •participate in other clinical trials within 4 week
- •prior radiation therapy within 2 week
结局指标
主要结局
Response Rate
时间窗: TTP, OS
次要结局
- - To determine the time to progression - To determine the response duration - To determine the overall survival - To determine toxicities - To determine the pharmacogenomic predictor (association study)(PFS, OS)
研究者
Seock-Ah Im
Professor
Seoul National University Hospital
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)Biliary Tract CancerNCT01180153Peking University Cancer Hospital & Institute40
Unknown
2 期
A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 SurgeryGastric CancerNCT01679340Peking University160
已完成
2 期
Phase II study of oxaliplatin reintroduction treated with biweekly S-1 plus oxaliplatin (SOX) in patients with metastatic colorectal cancer.(ORION2)Colorectal cancerJPRN-UMIN000013277Epidemiological and Clinical research Information Network (ECRIN)40
Unknown
1 期
Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant SettingRectal CarcinomaNCT01227239Japan Clinical Cancer Research Organization45
已完成
2 期
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaWaldenström MacroglobulinemiaNCT00006473National Cancer Institute (NCI)72